Sun Pharmaceutical Industries Ltd. delivered on its quarterly profit in July-September 2025, helped by strong demand for its drugs in India. Operational profitability, however, dipped.
Net profit of India’s largest drugmaker rose 2.6% over the year-ago period to ₹3,118 crore in the three months ended 30 September, on revenue that increased 8.9% year-on-year to ₹14,478 crore, according to an exchange filing on Wednesday (5 November 2025).
Sun Pharma Q2 FY26 Results (Consolidated, YoY)
- Revenue up 8.9% at ₹14,478 crore
- EBITDA up 7.5% at ₹4,067 crore
- EBITDA margin down 40 bps at 28.3%
- Net profit up 2.6% at ₹3,118 crore
One basis point is one-hundredth of a percentage point.
That quarterly performance came on the back of 11% growth in sales in India — its largest revenue-generating region.
Sun Pharma has been focusing on strengthening its portfolio of innovative drugs in dermatology, oncology and obesity therapy areas as it focuses on a mid-to-high single-digit percentage revenue growth in FY26.
Sales of innovative drugs, which is the company’s high-margin segment and includes medicines for conditions such as alopecia and psoriasis, rose nearly 16.4% to $333 million (about ₹2,950 crore).
US sales of innovative medicines have surpassed generics for the first time during the quarter, MD Kirti Ganorkar said, but overall US sales declined 4.1% to $496 million (about ₹4,400 crore).
India’s generic drugmakers, led by Sun Pharma, derive a significant share of revenue from the US, where lower drug prices due to stiff competition have been weighing on profit margins.